[Paliperidone--a novel second-generation antipsychotic].
Copyright policy )[Paliperidone--a novel second-generation antipsychotic].
Paliperidone Depot (PAL ER) is a new second-generation antipsychotic with pharmacodynamics resembling those of risperidone. PAL ER is slowly and smoothly released in 24 hours. Its half-life is about 24 hours. PAL is primarily eliminated unchanged in urine. Three short-term studies and one relapse study found PAL ER to be significantly more effective than placebo in all doses (3-15 mg once a day). There are no head-to-head comparisons with other antipsychotics, including risperidone. On the existing evidence it is not possible to ascertain whether PAL ER is better than risperidone in terms of effects and tolerability.
Evidence-Based Medicine, Pyrimidines, Treatment Outcome, Delayed-Action Preparations, Paliperidone Palmitate, Humans, Isoxazoles, Risperidone, Antipsychotic Agents, Half-Life
Evidence-Based Medicine, Pyrimidines, Treatment Outcome, Delayed-Action Preparations, Paliperidone Palmitate, Humans, Isoxazoles, Risperidone, Antipsychotic Agents, Half-Life
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!